Study Finds Increased Risk of MGUS in Vietnam Vets Exposed to Agent Orange
the ONA take:
Vietnam War veterans exposed to Agent Orange, an herbicidal agent used for warfare, have more than a 2-fold increased risk for monoclonal gammopathy of undetermined significance (MGUS), according to a new study published online ahead of print in JAMA Oncology.
MGUS is a precursor to multiple myeloma. Patients with MGUS have lower antibody levels, plasma cells in the bone marrow, and no symptoms. Therefore, no treatment is indicated for patients with MGUS, but patients should be followed up every 6 months to determine if MGUS has transformed into multiple myeloma or a similar lymphoproliferative disorder.
For the study, a team of researchers led by Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York analyzed samples from 958 male veterans of the Vietnam War. Half of those were Operation Ranch Hand veterans who participated in aerial Agent Orange spray missions.
"Our findings of increased MGUS risk among Ranch Hand veterans support an association between Agent Orange exposure and multiple myeloma," the study concludes.
Agent Orange was widely used during the Vietnam War.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|